Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Ozempic Alternatives Without Hypoglycemia Risk When Combined With Other Diabetes Drugs

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Ozempic alone, severe hypoglycemia / 0% on placebo, 0.5 mg and 1 mg over 30 weeks [1]
  • Ozempic alone, documented symptomatic (70 mg/dL or lower) / 0% placebo, 1.6% at 0.5 mg, 3.8% at 1 mg [1]
  • Ozempic added to basal insulin, documented symptomatic / 15.2% placebo, 16.7% at 0.5 mg, 29.8% at 1 mg [1]
  • Ozempic added to basal insulin, severe episodes or symptomatic confirmed at 56 mg/dL or lower / 5.3% placebo, 8.3% at 0.5 mg, 10.7% at 1 mg [1]
  • Ozempic label on the companion drug / consider reducing the sulfonylurea or insulin dose when starting [1]
  • Long-acting GLP-1 receptor agonists, 10-trial meta-analysis / no increased risk of severe hypoglycemia [3]
  • Tirzepatide vs semaglutide 1 mg (SURPASS-2) / hypoglycemia below 54 mg/dL in 0.2% to 1.7% vs 0.4% [4]

What the Ozempic label says

Semaglutide stimulates insulin release when blood glucose is already elevated [1]. In the label's 30-week monotherapy trial, severe hypoglycemia occurred in 0% of people on placebo, 0.5 mg and 1 mg, and documented symptomatic episodes at 70 mg/dL or lower occurred in 0%, 1.6% and 3.8% [1].

The risk changes when Ozempic is used with other glucose-lowering drugs. The label states that people taking Ozempic with an insulin secretagogue such as a sulfonylurea, or with insulin, may have an increased risk of hypoglycemia, including severe hypoglycemia, and that the risk may be lowered by reducing the dose of that drug. Its warning and interaction sections give no percentage for the reduction [1].

How much the risk rises with insulin

In the label's 30-week add-on-to-basal-insulin trial, with or without metformin and with 131 to 132 people per arm, documented symptomatic episodes at 70 mg/dL or lower occurred in 15.2% on placebo, 16.7% on Ozempic 0.5 mg and 29.8% on Ozempic 1 mg [1]. Severe episodes or symptomatic episodes confirmed by a blood glucose reading of 56 mg/dL or lower occurred in 5.3% on placebo, 8.3% on Ozempic 0.5 mg and 10.7% on Ozempic 1 mg, and severe episodes needing another person's help in 0%, 0% and 1.5% [1]. The label notes that hypoglycemia was more frequent when Ozempic was used with a sulfonylurea, and that Ozempic and insulin are given as separate injections and never mixed [1].

SUSTAIN 5 gives the patient counts: 397 adults on basal insulin with or without metformin over 30 weeks had severe or glucose-confirmed episodes in 11 people on semaglutide 0.5 mg and 14 on 1 mg versus 7 on placebo; the rate ratios of 2.08 and 2.41 were not statistically significant [2].

How other GLP-1-based options compare

In a meta-analysis of 10 placebo-controlled cardiovascular and kidney outcome trials of long-acting GLP-1 receptor agonists in 71,351 people with type 2 diabetes, there was no increased risk of severe hypoglycemia [3]. In SURPASS-2, a 40-week head-to-head trial of 1,879 patients, hypoglycemia (blood glucose below 54 mg/dL) was reported in 0.6%, 0.2% and 1.7% on tirzepatide 5, 10 and 15 mg versus 0.4% on semaglutide 1 mg [4].

Frequently asked questions

Does Ozempic cause low blood sugar by itself?
In the label's monotherapy trial, severe hypoglycemia occurred in 0% of people on placebo, 0.5 mg and 1 mg over 30 weeks, and documented symptomatic episodes at 70 mg/dL or lower occurred in 0%, 1.6% and 3.8% [1].
Which drugs does the label name as raising the risk with Ozempic?
Insulin secretagogues such as sulfonylureas, and insulin itself. On top of basal insulin, documented symptomatic episodes at 70 mg/dL or lower occurred in 15.2% on placebo, 16.7% on Ozempic 0.5 mg and 29.8% on 1 mg, and the label says hypoglycemia was more frequent with a sulfonylurea [1].
How did tirzepatide compare with semaglutide on low blood sugar in a head-to-head trial?
In SURPASS-2, hypoglycemia below 54 mg/dL was reported in 0.6%, 0.2% and 1.7% of the tirzepatide 5, 10 and 15 mg groups, versus 0.4% of the semaglutide 1 mg group [4].
Do GLP-1 receptor agonists as a group raise the risk of severe hypoglycemia?
A meta-analysis of 10 placebo-controlled trials of long-acting GLP-1 receptor agonists in 71,351 people with type 2 diabetes found no increased risk of severe hypoglycemia [3].

References

  1. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
  2. Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018;103(6):2291-2301. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
  3. Lee MMY, Sattar N, Pop-Busui R, Deanfield J, Emerson SS, Inzucchi SE, et al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care. 2025. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes
  4. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Evidence overview for Ozempic Alternatives Without Hypoglycemia Risk When Combined With Other Diabetes Drugs